Please use this identifier to cite or link to this item:
Title: Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient
Austin Authors: Murphy, C;Hawkes, E ;Chionh, Fiona;Chong, Geoff
Affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia
Issue Date: Feb-2017
Date: 2016-10-28
Publication information: Journal of Clinical Pharmacy and Therapeutics 2017; 42(1): 111-114
Abstract: WHAT IS KNOWN AND OBJECTIVE: Human herpesvirus-8 (HHV-8)-positive, HIV-negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV-8-related disease, is uncommon in HIV-negative patients. The role of antiviral therapy and rituximab in HIV-negative patients is not well established. CASE DESCRIPTION: We report a case of a 5-year, durable remission of HHV-8-positive, HIV-negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long-term valganciclovir, following initial rituximab and liposomal doxorubicin. WHAT IS NEW AND CONCLUSION: Currently, there is no defined role for antiviral therapy in the treatment of HIV-negative HHV-8-positive multicentric Castleman's disease and Kaposi's sarcoma. Ganciclovir followed by indefinite, continuous valganciclovir is thought to have contributed significantly to the durable response in this case.
DOI: 10.1111/jcpt.12472
Journal: Journal of Clinical Pharmacy and Therapeutics
PubMed URL:
Type: Journal Article
Subjects: Kaposi's sarcoma
Human herpesvirus-8
Multicentric Castleman's disease
Type of Clinical Study or Trial: Case Series and Case Reports
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.